Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

• DOI: 10.1126/scitranslmed.3008095
• Publication Date: 2014-03-05T19:10:38Z
• Authors: Dmitriy Zamarin; Rikke B. Holmgaard; Sumit K. Subudhi; Joon Seok Park; Mena Mansour; Peter Palese; Taha Merghoub; Jedd D. Wolchok; James P. Allison
• Keywords: CD4-Positive T-Lymphocytes; Inflammation; Oncolytic Virotherapy; 0301 basic medicine; Melanoma, Experimental; Newcastle disease virus; CD8-Positive T-Lymphocytes; 3. Good health; Killer Cells, Natural; Mice; Oncolytic Viruses; 03 medical and health sciences; Immune System; Interferon Type I; Animals; CTLA-4 Antigen; Immunotherapy; Lymphocytes; Neoplasm Transplantation

Intratumoral treatment with an oncolytic virus results in inflammatory infiltrates in distant tumors and sensitizes the tumors to immune-mediated rejection in the setting of immunotherapy with CTLA-4 blocking antibodies.